Methylphenidate transdermal system: In attention-deficit hyperactivity disorder in children

Area of Science:

• Pharmacology
• Pediatrics
• Neuroscience

Background:

• Attention-deficit hyperactivity disorder (ADHD) is a common neurodevelopmental disorder in children.
• Methylphenidate transdermal system (MTS) offers a sustained-release alternative to oral methylphenidate (MPH).
• MPH is a central nervous system stimulant affecting dopamine and noradrenaline pathways.

Purpose of the Study:

• To evaluate the efficacy and tolerability of the methylphenidate transdermal system (MTS) in pediatric patients with ADHD.
• To assess the pharmacokinetic profile of MPH delivered via the MTS patch.
• To compare the effectiveness of MTS patches against placebo in managing ADHD symptoms.

Main Methods:

• Utilized controlled trials involving children aged 6-12 years diagnosed with ADHD.
• Administered MTS patches releasing MPH doses of 10-30 mg over a 9-hour period.
• Monitored ADHD symptom improvement and recorded adverse events.

Main Results:

• MTS patches demonstrated significantly greater improvements in ADHD symptoms compared to placebo.
• Mean peak plasma concentrations of d-MPH were reached approximately 8 hours post-application.
• Adverse events were comparable to oral MPH and predominantly mild to moderate in intensity.

Conclusions:

• The methylphenidate transdermal system (MTS) is an effective and well-tolerated treatment option for pediatric ADHD.
• Sustained drug absorption via MTS provides consistent therapeutic levels for ADHD management.
• MTS offers a viable alternative for children requiring continuous MPH delivery for ADHD symptom control.